|1.||Li, Yue: 4 articles (05/2007 - 05/2005)|
|2.||Han, Wei: 4 articles (05/2007 - 05/2005)|
|3.||Li, Wei-min: 3 articles (05/2007 - 05/2005)|
|4.||Stanisz, Beata J: 2 articles (07/2014 - 11/2013)|
|5.||Paszun, Sylwia K: 2 articles (07/2014 - 11/2013)|
|6.||Sheng, Li: 2 articles (05/2007 - 01/2007)|
|7.||Dong, Deli: 2 articles (05/2007 - 01/2007)|
|8.||Chazova, I E: 2 articles (01/2007 - 01/2005)|
|9.||Pustovitova, T S: 2 articles (01/2007 - 01/2005)|
|10.||Sinitsyn, V E: 2 articles (01/2007 - 01/2005)|
|1.||Hypertension (High Blood Pressure)
12/01/1995 - "Cilazapril is an effective treatment for hypertension in this model of progressive renal disease and may have benefits beyond the prevention of cardiovascular morbidity."
01/01/1994 - "Cilazapril is effective in reducing BP in all situations, especially during REM sleep hypertension."
06/01/1993 - "In conclusion, these data demonstrate that cilazapril 5 mg/day is effective in reducing blood pressure in mild-to-moderate essential hypertension. "
01/01/1992 - "(c) Is the effect of cilazapril only preventive or can cilazapril also be effective when hypertension is already present? "
12/26/1989 - "Cilazapril appears to be an effective and safe antihypertensive drug in patients with hypertension and renal disease."
01/01/1994 - "Up to 86% of patients receiving these dosages had improvement, with only 12% of patients requiring the higher dose, 5 mg. These data indicate that cilazapril is effective when administered once daily to patients with chronic heart failure receiving concomitant therapy with digitalis and/or a diuretic. "
11/01/2002 - "In conclusion, short-term cilazapril administration improved endothelial function and pulmonary pressure in patients with congestive heart failure."
05/01/1991 - "In small studies cilazapril has produced sustained beneficial haemodynamic effects in patients with congestive heart failure. "
01/01/1989 - "A pharmacokinetic study of cilazapril in patients with congestive heart failure."
07/01/2014 - "Abstract: Cilazapril is a drug commonly used in management of heart failure in pediatric population. "
05/01/1993 - "A significant reduction in LV hypertrophy and an improved diastolic filling pattern of the left ventricle was shown after six months of therapy with cilazapril; this improvement still remained after 1 year of therapy. "
01/01/1991 - "A significant reduction in LV hypertrophy and an improved diastolic filling pattern of the left ventricle was shown after 6 months of therapy with cilazapril; this improvement still remained after 1 year of therapy."
10/01/2002 - "Group 2 unclipped kidneys showed hypertrophy, which remained unaffected by cilazapril treatment. "
07/01/2000 - "Before cilazapril therapy, LV diastolic function and carotid artery distensibility were significantly impaired in 32 patients with residual LV hypertrophy compared with patients without LV hypertrophy. "
01/01/1996 - "Cilazapril is an ACE long duration agent which produces a reduction of both blood pressure and cardiovascular hypertrophy. "
|4.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/01/2002 - "Mono- and combined therapy with cilazapril proved effective in the above patients as it optimally lowered blood pressure and induced a reverse development of left ventricular hypertrophy. "
06/01/1993 - "[The regression of left ventricular hypertrophy and improvement in diastolic filling during antihypertensive therapy with cilazapril]."
05/01/1993 - "Moreover, in long treatment, cilazapril has been useful to reduce left ventricular hypertrophy and to improve diastolic filling without significant side effects."
04/23/1993 - "We assessed the acute effects of 2.5 mg oral cilazapril on systemic and coronary hemodynamics in seven renovascular hypertensive patients with a chronically overactive renin-angiotensin system (RAS), but with no electrocardiographic or echocardiographic signs of left ventricular hypertrophy. "
01/01/1990 - "Long-term treatment with cilazapril, caused regression of left ventricular hypertrophy. "
06/01/1992 - "Cilazapril provided protection against the deleterious remodeling changes such as ventricular dilation and wall thinning consequent to acute myocardial infarction."
11/01/1996 - "Effects of cilazapril on exercise tolerance in the chronic phase of acute myocardial infarction."
07/01/1992 - "Clinical events during 6-month follow-up, analyzed on an intention-to-treat basis, were ranked according to the most serious clinical event ranging from death (control, two; cilazapril, three), nonfatal myocardial infarction (control, eight; cilazapril, 5), coronary revascularization (control, 51; cilazapril, 53), or recurrent angina requiring medical therapy (control, 67; cilazapril, 68) to none of the above (control, 224; cilazapril, 212). "
06/01/1992 - "Effect of cilazapril on regional left ventricular wall thickness and chamber dimension following acute myocardial infarction: in vivo assessment using MRI."
11/01/1995 - "In patients with asymptomatic left ventricular dysfunction after myocardial infarction, 8 week's cilazapril administration improved exercise tolerance and neurohumoral conditions."
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|4.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|4.||Angioplasty (Angioplasty, Transluminal)